DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...

The UBS CIO Americas wealth management equity sector strategy team came out and spotlighted its 30 most preferred stocks ...

Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...